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Abstract 
Purpose: To prepare and characterize buccal transmucosal delivery system of enalapril maleate for 
overcoming its low bioavailability, and hence provide improved therapeutic efficacy and patient 
compliance.  
Methods: Transmucosal drug delivery systems of enalapril maleate were formulated as buccal films by 
solvent casting technique using polyvinylpyrrolidone K90, hydroxypropyl methylcellulose, sodium 
carboxymethylcellulose (high viscosity). The films were evaluated for film weight, thickness, folding 
endurance, drug content uniformity, surface pH, in vitro residence time, in vitro drug release and ex-vivo 
permeation. 
Results: All the formulations showed high drug content (96.45 to 98.49 %). Those with good swelling 
showed good residence time. In vitro drug release was highest for films prepared with high viscosity 
grade sodium carboxymethylcellulose (SCMC- HV,F2), releasing 92.24 % of drug in 1.5 h) followed by 
F4 (containing polyvinyl pyrrolidone K-90 1 % w/v and SCMC (HV) 1 % w/v). Ex-vivo drug permeation at 
the end of 10 h was 82.24 and 89.9 % for F2 and F4, respectively.  
Conclusion: Prompt drug release was obtained from the formulation (F2) containing SCMC 2 % w/v 
with 10 mg enalapril. However, on the basis of the highest swelling and residence time, and controlled 
drug release, formulation F4 (containing PVP K-90 and SCMC HV) would be suitable for the 
development of buccal film for effective therapy of cardiac diseases.  
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In recent years transmucosal drug delivery 
systems (TMDDSs) have been investigated for 
delivering the drugs across the various different 
mucosa (like oral, buccal, nasal, vaginal or 
rectal) for gaining various advantages across the 
conventional oral dosage forms. These 
advantages include providing prompt action, 
preventing the hepatic first pass metabolism, 
reducing the gastrointestinal irritation and 
reducing the dosage frequency [1,2]. The 
transmucosal delivery occurs when a drug 
delivery system is kept in intimate contact of a 
mucous membrane (buccal, vaginal, nasal, rectal 
etc.) for an extended period of time [3]. The 
bioadhesion occurs due to swelling of delivery 
system (due to imbibement of mucous) which 
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follows the entanglement of polymer chains with 
that of mucin molecules. After the chain 
entanglement the drug diffuses across the 
mucosa [1,3,4]. 
 
Among the various mucosae the buccal mucosa 
is best suited for local as well as systemic 
delivery of drugs. Its properties such as high 
vascularization, circumvention of the first pass 
metabolism and better patient compliance (than 
other mucosal sites) make it as an ideal route for 
transmucosal drug delivery [4-7]. Moreover, the 
improved bioavailability over the other sites 
available for TMDDS is the vital factor associated 
with transmucosal buccal drug delivery. These 
dosage forms are economic and patient friendly 
also.  
 
The microenvironment of the mucosa governs 
the drug dissolution (release) and permeation 
through the mucosa; and the properly designed 
TMDDS can modulate it [8]. Mucoadhesive 
polymers are used for the formulation of TMDDS. 
These polymers generally are the polymers and 
their different grades with high molecular weight, 
high viscosity, greater flexibility and optimum 
chain length [9-13]. 
 
Transmucosal buccal delivery has been 
investigated for various drugs including protein 
and peptides [14-17]. Various TMDDS like 
tablets, films, patches, disks, strips, ointments 
and gels have been investigated [14-21]. Out of 
these transmucosal buccal films have been 
reported to be more flexible, comfortable with 
relatively longer residence time (than that of oral 
gels) on the mucosa. These films also show 
more protectant effect on the local wound 
surface for oral diseases [21-23].  
 
Enalapril maleate is an angiotensin converting 
enzyme (ACE) inhibitor, used mainly in the 
treatment of hypertension and angina pectoris. It 
has low bioavailability (40 – 60 %) due to hepatic 
first pass metabolism [24-26].  Hence to improve 
its therapeutic efficacy and bioavailability, the 
drug may be administered by buccal route using 
buccal films. Buccal delivery of enalapril maleate 
may circumvent hepatic first pass metabolism to 
improve its bioavailability. Hence the present 
study aimed to formulate and characterize 
transmucosal buccal films of enalapril maleate 
with the use of mucoadhesive polymers, 
including sodium carboxymethylcellulose 
(SCMC), hydroxylpropyl methylcellulose 
(HPMC), hydroxyethylcellulose (HEC) and 




Enalapril maleate, PVP K-90, HPMC (47 
centipoise), SCMC (high viscosity grade) were 
obtained from Sigma Aldrich, US. Other 
chemicals used were of analytical grade. The 
films were prepared using solvent casting 
method.  
 
Preparation of transmucosal buccal films 
 
Buccal films of enalapril maleate were prepared 
by solvent casting technique using film forming 
mucoadhesive polymers based on the 
composition in Table 1. 
 






F1 F2 F3 F4 F5 F6 
Drug 2 2 2 2 2 2 
PVP K-90 2 - - 1 1 - 
HPMC K15 - - 2 - 1 1 
SCMC (HV) - 2 - 1 - 1 
Abbreviations: PVP - polyvinylpyrrolidone, HPMC - 
hydroxypropylmethylcellulose, SCMC (HV) - sodium 
carboxymethylcellulose (high viscosity grade) 
 
HPMC was weighed (100 mg) accurately and 
dissolved in minimum ethanol. After the swelling 
of polymer solution (standing time 10 min) more 
(5 ml) ethanol was added to the swelled polymer 
solution and the dispersion was kept for stirring 
(400 rpm, 15 min). To this solution, propylene 
glycol was added. Ethanolic enalapril maleate 
solution was prepared and added to the polymer 
solution. The solution was vortexed and then 
stirred for 15 min at 400 rpm. The resulting 
solution was filled into vials, leaving little space 
over the surface and kept overnight. This step 
removed any air bubble in the drug-polymer 
solution. The bubble free drug polymer solution 
was poured into glass Petri dish placed over a 
flat surface with Inverted funnel placed over the 
dish (to avoid sudden evaporation). These Petri 
dish were kept for 12 h at room temperature for 
drying and solvent evaporation. The prepared dry 
films were removed, cut into size of 2 cm 
diameter, kept in butter paper and stored in a 
desiccator till further use.  
 
Determination of film weight, thickness and 
folding endurance 
 
Film weight (by digital balance, Fisher Brand PS-
200) and thickness (by micrometer screw gauge, 
Mitutoyo MMO-25DS) were determined (n = 3). 
Folding endurance was determined by 
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repeatedly folding a small strip of size (2 × 2 cm) 
of film at the same place till it broke (Table 2). 
 
Drug content uniformity measurement 
 
To determine the drug content uniformity, three 
film units of each formulation were taken in 
separate 100 ml volumetric flasks, 100 ml of 
methanol was added and continuously stirred for 
4 h (till all the contents are dissolved). The 
solutions were filtered, diluted suitably and 
analyzed at 213 nm in a UV spectrophotometer 
(Lambda 25, Perkin Elmer, US). The mean value 
of drug content of three films was taken. 
 
Measurement of surface pH 
 
Surface pH was determined by pH meter after 
keeping the hydrated films on agar plate for 1h 
for swelling [27,28].The swelling study was 
performed in pH 6.6 phosphate buffer by a 
previously reported [28]. 
 
Determination of in vitro residence time 
 
In vitro residence time was determined using 
USP disintegration apparatus using pH 6.6 
phosphate buffer (PB) as the disintegration 
medium (800 ml, 37 ± 2 oC). On the surface of a 
glass slab the segments of rat intestinal mucosa 
(each of 3 cm length) were glued and then the 
slab was vertically attached to the apparatus. 
Three films of each formulation were hydrated 
(on one surface using pH 6.6 PB) and the 
hydrated surface was brought into contact with 
the mucosal membrane. The glass slab was 
vertically fixed to the apparatus and allowed to 
move up and down. The film was completely 
immersed in the buffer solution at the lowest 
point and was out at the highest point. The time 
required for complete erosion or detachment of 
the film from the mucosal surface was recorded 
(n = 3) as given in Table 2. 
 
Evaluation of in vitro drug release 
 
In vitro drug release study was performed in a 
USP XXIV 8-station dissolution apparatus, type 
1, with 900 ml pH 6.6 phosphate buffer (PB) as 
dissolution medium, maintained at 37 ± 0.5 oC 
and 50 rpm for 6 h.  One film of each formulation 
was fixed to the central shaft using an adhesive. 
At predetermined time samples were withdrawn 
from each station, filtered, diluted suitably and 
then analyzed spectrophotometrically at 213 nm.  
 
Ex vivo permeation study 
 
Ex vivo permeation studies of mucoadhesive 
buccal films of enalapril through an excised layer 
of porcine buccal mucosa (washed with pH 7.4 
PB and trimmed to remove additional tissues 
before using) were carried out using the modified 
Franz diffusion cell[17,28-30]. A 2.0 cm diameter 
film of each formulation under study was placed 
in intimate contact with the excised porcine 
buccal mucosa and the topside was covered with 
aluminum foil as a backing membrane. The 
contents of receptor compartment filled with 100 
ml of pH 7.4 phosphate bufferwere stirred on a 
magnetic stirrer at 37 ± 10. The samples were 
withdrawn at predetermine time (replaced with 
same volume of fresh media), filtered, diluted 
suitably and then analyzed using UV 




The results are expressed as mean ± standard 
deviation (SD). Statistical analysiswas carried out 
by analysis of variance (ANOVA) using SPSS 
software (IBM SPSS Statistics 2015). P < 0.05 




Film weight, thickness and folding endurance 
 
The films showed uniform thickness throughout. 
The film thickness was found to be from 0.140 ± 
0.017 to 0.220 ± 0.034 mm (Table 2). 
 
The weights of different formulation were found 
to be in the range of 56 ± 1.02 mg to 94 ± 0.82 
mg. Folding endurance was measured manually 
by folding the film repeatedly at a point till they 
broke. Films did not show any cracks even after 
folding for more than 197 times. The folding 
endurance was found to be in the range of 




The percent drug content was found to be in the 





The surface pH of all formulations was within ± 
0.5 units of the neutral pH (6.4 to 6.8) and hence 
no mucosal irritation were expected and 




Swelling of the films in phosphate buffer solution 
(PBS, pH 6.6)  
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±0.50 



























































Data are expressed as mean ± SD (n = 3) 
 
was more pronounced in film F4 (48.11 ± 1.09) 
followed by F6 (47.90 ± 1.29) which contained 
PVP– SCMC and HPMC-SCMC, respectively 
(Table 2). 
 
In vitro residence time 
 
The in vitro residence time of various 
formulations was in the rank order of F4 > F6> 
F5 > F3 > F2 > F1. The in vitro residence time of 
the films were found to be in good tune with 
swelling and drug release properties. 
 
In vitro drug release 
 
In vitro release studies of various formulations 
were performed in PBS as dissolution medium. 
Significant difference in drug release was found 
for the various transmucosal buccal films of 




Fig 1: In vitro drug release study: Cumulative percent 
drug release of transmucosal buccal films in pH 6.6 
phosphate buffer for formulation F1 (-♦-); F2 (-□-); F3 
(-▲-); F4 (-×-); F5(-*-) and F6 (-⃝-) 
 
SCMC (HV) containing film (F2) showed highest 
drug release (with rapid release of drug, 92.24 % 
in 1.5 h).After the formulation F2, the formulation 
F4 (containing PVP K-90 1 % w/v and SCMC 
(HV) 1 % w/v) showed the better drug release. 
 
Ex-vivo drug release 
 
For ex-vivo drug release study the formulation F2 
(containing SCMC 2 % w/v) and F4 (containing 
PVP K-90 1 % w/v and SCMC HV 1 % w/v) were 
selected.  The formulation F2 was selected due 
to highest and fastest in vitro drug release while 
F4 was selected due to highest swelling, longest 
residence time and rapid (83.48 % in 1.5 h) as 
well as higher in vitro drug release (92.24 % at 
the end of 5 h). In ex vivo study, drug permeation 
through the porcine buccal mucosa was 




Fig 2: Ex-vivo permeation studies of selected 
transmucosal buccal films of enalapril maleate; 
Permeation studies in pH 7.4 phosphate buffer of 
formulations F2 (-□-) containing SCMC 2 % w/v, and 
F4 (-▲-) containing PVP K-90 1 % w/v and SCMC 1 % 
w/v with 10 mg enalapril in each film of 2 cm diameter 
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The ex-vivo drug permeation at the end of 10 h 
was 82.24 % and 89.9 % for F2 and F4, 
respectively. The correlation coefficient values 
were 0.9274 and 0.945 for F2 and F4, 
respectively showing good correlation. It was 
concluded that the release kinetics followed zero 
order. As the Higuchi plots of F2 and F4 showed 
linearity (with correlation coefficient values of 
0.910 and 0.958 for F2 and F4, respectively) the 
drug permeation was confirmed to be through the 




In cardiac diseases, prompt delivery of the drug 
is important especially in emergency situations. 
Moreover, when a patient is in capable of 
swallowing medicaments orally the alternative 
routes with improved bioavailability such as 
buccal route have been found to be very 
promising. 
 
The physical properties of buccal films like 
thickness weight, folding endurance values were 
found to be optimum to reveal good film 
properties. The higher drug loading values of the 
films indicated the uniform dispersion of drug in 
the prepared films which makes the loading and 
delivery of therapeutic dosage of the drug.   
 
The acidic or alkaline pH may be a potential 
irritant to the buccal mucosa with adverse effect 
on the drug release and degree of hydration of 
polymers. Therefore the surface pH of buccal film 
was determined to optimize both drug release 
and mucoadhesion. The pH of films being in 
good tune with the pH of buccal mucosa would 
not be expected to cause irritation and to affect 
adversely the drug release or hydration of 
polymers. The greater swelling property of 
SCMC (HV) was found to play a key role. 
 
The enhanced erosion rate associated with the 
non-ionic polymers (HPMC and SCMC) in the 
present study is well supported by the various 
previous studies [28,31,32]. The mucous and the 
biological fluid (pH 6.6) of buccal region gets 
imbibed into the transmucosal delivery system 
and this induction of swelling of particles in the 
matrix (of drug-polymer) make the transmucosal 
device a highly porous swollen matrix. The drug 
starts diffusing out of the highly porous matrix 
with simultaneous erosion of the polymer matrix. 
So the swelling property is closely associated 
with the residence time of buccal transmucosal 
film. 
 
In in vitro drug release studies, formulation F2 
showed rapid and the best release due to easy 
erosion of the polymer matrix which could not 
hold the drug for longer period of time as 
compared to other formulations. However, the 
formulation can be acceptable for the prompt 
delivery of the drug in cardiac emergencies. 
 
On the basis of the properties of high swelling, 
long residence time, high and fast in vitro drug 
release, formulations F2 and F4 were selected 
for ex vivo studies across the porcine buccal 
mucosa. Due to the low permeability of mucosa 
and unidirectional flow of drug flux (due to 
presence of backing membrane in ex vivo study) 
the drug permeation was slower and lower as 
compared to the in vitro drug release. The zero 
order of drug release with matrix diffusion 
process as shown by the formulations in the ex 
vivo studies, was best suited for getting the 
better cardiac effects of enalapril through the 




All the formulations showed good 
physicochemical properties including drug 
loading, swelling and in vitro residence properties 
and can be used for buccal transmucosal drug 
delivery of enalapril for delivery to systemic 
circulation for prompt or prolonged action 
depending on the polymers employed in 
developing the buccal films. However, in vivo, 
preclinical and clinical investigations need to be 
carried out before the findings can be translated 
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